Old Mission Capital’s Adicet Bio ACET Stock Holding History

Old Mission Capital’s Portfolio ACET Stock Details ACET Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-380	Closed	-$92K	–	417
2020 Q2	$92K	Buy	+380	New	+$74.7K	0.01%	433

Other funds holding ACET

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

JJIJ

Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Old Mission Capital's ACET Position: Q3 2020 in Review

Old Mission Capital sold out of Adicet Bio (ACET) in Q3 2020, closing a stake of 380 shares — an estimated $92K sold.

Old Mission Capital first reported a position in ACET in Q2 2020 and held it in 1 quarter. The position peaked at $92K in Q2 2020. 32 funds tracked by Wall St. Rank hold ACET as of Q3 2020.

Old Mission Capital reported no remaining Adicet Bio position as of Q3 2020 after selling out during the quarter.
Old Mission Capital sold 380 Adicet Bio shares in Q3 2020, an estimated $92K.
Old Mission Capital first reported a position in Adicet Bio in Q2 2020 and held it in 1 quarter.
Old Mission Capital's Adicet Bio position peaked at $92K in Q2 2020.
32 funds tracked by Wall St. Rank held Adicet Bio as of Q3 2020.

Based on Old Mission Capital's 13F filing for Q3 2020, filed 16 Nov 2020.